The largest database of trusted experimental protocols

7 protocols using aluminum hydroxide gel

1

OVA-Induced Asthma Model and CTS Treatment

Check if the same lab product or an alternative is used in the 5 most similar protocols
Mice were randomly separated into the following five groups: control group (n = 8), OVA group (ovalbumin, Sigma Co., St. Louis, MO, USA; n = 8), OVA+CTS 20 (CTS 20 mg/kg; Abcam, ab120666; Purity > 97% with chemical structure shown in Figure 1A; n = 8), OVA+CTS 40 (CTS 40 mg/kg; n = 8), and OVA+DEX (dexamethasone 1 mg/kg; Sigma Co., St. Louis, MO, USA; n = 8). The mice were sensitized on day 0, 7, and 14 by intraperitoneal injection of 20 µg OVA emulsified in 2 mg of aluminum hydroxide gel (InvivoGen, San Diego, CA, USA) in a total volume of 200 µl. These sensitized mice were exposed to aerosolized 5% OVA in sterile saline for three times (30 min each time) a week for 8 weeks beginning on day 16. The mice were placed in chambers (18×14×8 cm) connected to an ultrasonic nebulizer (NE-U11B; Omron Corp., Tokyo, Japan) to obtain a whole-body inhalation. CTS and DEX were administered through intraperitoneal injection at 30 min before nebulization (Figure 1B). Control mice were sensitized and challenged with phosphate buffered saline (PBS) using the same protocol. The mice were sacrificed at 48 h after the last challenge, and bronchoalveolar lavage fluid (BALF) and lung tissues were collected for analysis.
+ Open protocol
+ Expand
2

Investigating Galangin's Effects on Allergic Asthma

Check if the same lab product or an alternative is used in the 5 most similar protocols
Figure 1B shows a schematic illustration of the protocols. In total, 48 female BALB/c mice were randomly divided into the following 6 groups: control, OVA (Grade V; Sigma, St. Louis, MO, USA), OVA+GL (galangin 0.1 mg/kg; Sigma), OVA+GH (galangin 0.5 mg/kg), OVA+DEX (1 mg/kg; Sigma), and OVA + DMSO (0.4 μL in a total volume of 200 μL with saline, vehicle; Sigma). The mice were sensitised on days 0, 7 and 14 by intraperitoneal injection of 20 μg OVA emulsified in 2 mg of aluminum hydroxide gel (Invivo-Gen, San Diego, CA, USA) in a total volume of 200 μL. These sensitised mice were exposed to aerosolised 5% OVA in sterile saline for 8 weeks beginning on day 16 for 30 min three times a week. We placed the mice in chambers (51 × 31 × 21 cm) connected to an ultrasonic nebuliser (NE-U11B; OmronCorp., Tokyo, Japan) to obtain a whole-body inhalation system. Galangin (0.1 and 0.5 mg/kg), DEX and DMSO were administered 30 min before nebulisation. Control subjects were sensitised and challenged with saline using the same protocol. The mice were sacrificed 24 h after the last challenge, and BALF, sera, and lung tissues were collected for analysis.
+ Open protocol
+ Expand
3

Ovalbumin-Induced Asthma Model with PEDF

Check if the same lab product or an alternative is used in the 5 most similar protocols
Thirty two mice were randomly divided into the control, OVA, PEDF low and PEDF high groups. On Days 0 and 14, the mice in the OVA, PEDF low, and PEDF high groups were immunized by intraperitoneal injection of 100 µg of chicken egg ovalbumin (OVA, Grade V; Sigma, St Louis, MO, USA) emulsified in 100 µL of aluminum hydroxide gel (InvivoGen, San Diego, CA, USA). On day 21, the mice were placed in a Plexiglas box (29×22×18 cm) and were airway challenged with 1% aerosolized OVA for 30 minutes per day, 3 days per week, for a period of 8 weeks. The mice in the PEDF low and high groups were given injections via the tail vein with 50 or 100 µg/kg body weight of recombinant PEDF protein13 (link) (Peprotech, Rocky Hill, NJ, USA) before each OVA challenge. The mice in the control group received sensitization and airway challenge with phosphate-buffered saline (PBS) instead of OVA.
+ Open protocol
+ Expand
4

Purification and Formulation of SARS-CoV-2 NP

Check if the same lab product or an alternative is used in the 5 most similar protocols
NP of SARS-CoV-2 (418 amino acids) was cloned and purified from E. coli as previously reported [26 (link)]. This protein was mixed at a ratio of 9 : 1 with aluminum hydroxide gel (InvivoGen).
+ Open protocol
+ Expand
5

CpG-ODN Adjuvant Immunization Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
CpG-ODN were purchased from Invitrogen or Genomics Biosci and Tech. Ovalbumin and aluminum hydroxide gel were purchased from Invivogen. Freund’s complete adjuvant and incomplete adjuvant were purchased from Thermo Scientific. Luciferase assay reagents were purchased from Promega.
+ Open protocol
+ Expand
6

Immunization Protocol for IsdB Antigen

Check if the same lab product or an alternative is used in the 5 most similar protocols
Mice were immunized i.p. three times with IsdB (75μg, 50μg and 50μg) plus aluminum hydroxide (Aluminum hydroxide gel, InvivoGen, vac-alu-250) (450μg per dose) or with aluminum hydroxide alone at 7-day intervals. Mouse sera were screened for reactivity to IsdB by ELISA.
+ Open protocol
+ Expand
7

Influenza A Virus Vaccine Adjuvant Evaluation

Check if the same lab product or an alternative is used in the 5 most similar protocols
The influenza A virus (A/New Caledonia/20/99; H1N1) SV and WPV were generously provided by the Kitasato Institute (Tokyo, Japan). WPV (whole-virion preparation of an inactivated influenza virus comprising three different types of inactivated whole-virion components: A/Newcaledonia/20/99 (H1N1), A/Hiroshima/52/2005 (H3N2), and B/Malaysia/2506/2004) used for leukopenic toxicity test were obtained from KM Biologics Co., Ltd. (Kumamoto, Japan). The following commercially available adjuvants were used: Aluminum hydroxide gel (Alhydrogel, alum), squalene-based oil-in-water adjuvant AddaVax, murine stimulator of interferon genes (STING) ligand DMXaa, toll-like receptor 1/2 (TLR1/2) agonist Pam3CSK4, TLR3 agonist Poly I:C, and TLR7/8 agonist R848 obtained from InvivoGen (San Diego, CA, USA). Silicon dioxide nanopowder (NanoSiO2, particle size 10–20 nm) was obtained from Sigma-Aldrich (MA, USA). The TLR9 agonist CpG K3 was generously provided by Prof. Ken J Ishii (The Institute of Medical Science, The University of Tokyo, Tokyo, Japan).
The dose and inoculation volume of influenza vaccine antigens and adjuvants are outlined in Table 2. The appropriate quantity of each adjuvant was mixed with SV and the final volume was unified in each experiment, as described in Table 2. Intranasal inoculation was performed after anesthetization by intraperitoneal injection of sodium phenobarbital.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!